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ABSTRACT
As a herpesvirus, Epstein-Barr virus (EBV) establishes a latent infection that can periodically undergo reactivation, resulting in
lytic replication and the production of new infectious virus. Latent membrane protein-1 (LMP1), the principal viral oncoprotein,
is a latency-associated protein implicated in regulating viral reactivation and the maintenance of latency. We recently found that
LMP1 hijacks the SUMO-conjugating enzyme Ubc9 via its C-terminal activating region-3 (CTAR3) and induces the sumoylation
of cellular proteins. Because protein sumoylation can promote transcriptional repression, we hypothesized that LMP1-induced
protein sumoylation induces the repression of EBV lytic promoters and helps maintain the viral genome in its latent state. We
now show that with inhibition of LMP1-induced protein sumoylation, the latent state becomes less stable or leakier in EBV-
transformed lymphoblastoid cell lines. The cells are also more sensitive to viral reactivation induced by irradiation, which re-
sults in the increased production and release of infectious virus, as well as increased susceptibility to ganciclovir treatment. We
have identified a target of LMP1-mediated sumoylation that contributes to the maintenance of latency in this context: KRAB-
associated protein-1 (KAP1). LMP1 CTAR3-mediated sumoylation regulates the function of KAP1. KAP1 also binds to EBV
OriLyt and immediate early promoters in a CTAR3-dependent manner, and inhibition of sumoylation processes abrogates the
binding of KAP1 to these promoters. These data provide an additional line of evidence that supports our findings that CTAR3 is
a distinct functioning regulatory region of LMP1 and confirm that LMP1-induced sumoylation may help stabilize the mainte-
nance of EBV latency.
IMPORTANCE
Epstein-Barr virus (EBV) latent membrane protein-1 (LMP1) plays an important role in the maintenance of viral latency. Previ-
ously, we documented that LMP1 targets cellular proteins to be modified by a ubiquitin-like protein (SUMO). We have now
identified a function for this LMP1-induced modification of cellular proteins in the maintenance of EBV latency. Because
latently infected cells have to undergo viral reactivation in order to be vulnerable to antiviral drugs, these findings identify a new
way to increase the rate of EBV reactivation, which increases cell susceptibility to antiviral therapies.
Epstein-Barr virus (EBV) is a ubiquitous human gammaherpes-virus that causes persistent infection, generally asymptomatic,
in over 90% of the world’s population. Initially, the virus lytically
infects oropharyngeal epithelial cells, producing virions contain-
ing linear genomes. The virus also quickly infects B lymphocytes,
in which latent infection is established and persists in the form of
episomes and subsets of viral latency genes are expressed. Period-
ically, latent virus can be reactivated and infectious virus is re-
leased in saliva (1). The processes that regulate the switch between
latent and lytic infection have been studied for many years. One
viral gene implicated in effecting this switch is latent membrane
protein-1 (LMP1) (2–4), the principal oncoprotein of EBV.
LMP1, which is expressed in type II latency (Hodgkin’s lym-
phoma and nasopharyngeal carcinoma [NPC]) and in type III
latency (B-cell lymphomas in immunocompromised persons) (5–
7), is an integral membrane signaling protein that mimics the
tumor necrosis factor (TNF) receptor family members (such as
CD40), with the exception that its activation is ligand independent
and it is constitutively active (8). LMP1 consists of a short cyto-
plasmic N-terminal domain, six transmembrane domains, and a
200-amino-acid cytoplasmic C-terminal domain. The carboxyl
terminus contains three C-terminal activating regions (CTARs;
CTAR1 to CTAR3) (8, 9); most LMP1-mediated signal transduc-
tion events are mediated via the extensively characterized CTAR1
and CTAR2. Functions for CTAR3 are less well defined (10–13);
however, we recently documented a novel function for CTAR3 in
the dysregulation of sumoylation processes (14).
Protein sumoylation is a posttranslational modification char-
acterized by the covalent, yet reversible, attachment of a small
ubiquitin-like modifier (SUMO), a 12-kDa protein that shares
20% homology with ubiquitin (15), to a lysine residue of a target
protein. It is a dynamic and reversible process that can regulate
protein function by altering a protein’s intracellular location,
turnover, ability to interact with other proteins, or ability to inter-
act with DNA (15–17). Protein sumoylation is involved in central
cellular processes, and multiple oncogene and tumor suppressor
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proteins undergo sumoylation, altering their function (18–23).
Furthermore, increases in protein sumoylation are a feature of a
variety of types of cancer (24–27), and because cellular sumoyla-
tion processes are thought to be critical in regulating oncogenesis,
elements of the sumoylation process have been proposed to be
potential new targets for cancer therapies (26, 28).
Sumoylation processes have a role in the EBV life cycle (29–
37). We documented that LMP1 CTAR3 physically interacts with
the enzymatically active SUMO-conjugating enzyme Ubc9 during
latent EBV infections (14), increases the sumoylation of cellular
proteins, and contributes to basic features of the oncogenic phe-
notype produced by LMP1 (14). Our preliminary data have iden-
tified two additional mechanisms by which LMP1 regulates
sumoylation processes: first, through the induction of sumo and,
second, through the inhibition of desumoylating enzymes (un-
published data). Together, these findings led us to investigate as-
pects of the function of LMP1 in mediating the regulation of
sumoylation processes during latent EBV infection.
One documented function of LMP1 is to help maintain viral
latency (2–4). The conditional expression of LMP1 has been
shown to inhibit EBV reactivation (2). LMP1-induced signaling
also helps modulate the antiviral environment within latently in-
fected cells (38–45), and our recent studies highlight a role for
LMP1 CTAR3-induced sumoylation in modulating this antiviral
environment (46). Sumoylation processes aid in transcriptional
repression (47–49), and we have reported that LMP1 CTAR3-
mediated sumoylation results in transcriptional repression (46).
Therefore, we hypothesize that LMP1 induces, via CTAR3, the
sumoylation of cellular proteins, which collectively promote tran-
scriptional repression and help sustain the EBV latent state. Ac-
cordingly, inhibition of protein sumoylation might be expected to
increase viral reactivation and result in increased cell susceptibility
to drugs and other agents that inhibit viral replication.
We show here that LMP1-induced sumoylation contributes to
the LMP1-mediated maintenance of EBV latency. Inhibition of
LMP1-induced sumoylation results in the disruption of latency
and viral reactivation as well as increased susceptibility to ganci-
clovir (GCV) treatment. In addition, we have identified a target of
LMP1-induced sumoylation (KRAB-associated protein-1 [KAP1])
that contributes to the maintenance of EBV latency. KAP1 is a
member of the tripartite motif family, is involved in transcrip-
tional repression, and is thought to have antiviral activities (50–
54). The endogenous sumoylation of KAP1, which occurred in an
LMP1 CTAR3-dependent manner, was detected in EBV-trans-
formed lymphoblastoid cell lines (LCLs). Further, we found that
LMP1 CTAR3 and inhibition of cellular sumoylation processes
affect KAP1 function in the context of chromatin association, a
known requirement for KAP1-mediated transcriptional repres-
sion (53, 54). We also show that KAP1 binds to EBV OriLyt and
immediate early promoters and inhibition of LMP1 CTAR3-in-
duced protein sumoylation abrogates the binding of KAP1 to
these promoters. These combined effects point to roles for LMP1-
induced sumoylation, acting through CTAR3, in the maintenance
of EBV latency.
MATERIALS AND METHODS
Cells. Human embryonic kidney (HEK) 293 cells (293 cells) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) plus 10% fetal
bovine serum (FBS). EBV-negative BL41 cells, BL41 cells infected with
wild-type (WT) EBV, and BL41 cells infected with an EBV mutant
(P3HR1 [55–57]), as well as Raji cells, were maintained in RPMI plus 10%
FBS. EBV-expressing 293 cells and 293 cells expressing EBV with a CTAR3
deletion (dCTAR3) were a gift from Wolfgang Hammerschmidt (Mu-
nich, Germany) and maintained in RPMI with 10% FBS and hygromycin
B (58). Paired EBV WT-transformed and EBV dCTAR3-transformed
LCLs were made by the Lineberger Comprehensive Cancer Center Tissue
Culture Facility and cultured in RPMI plus 10% FBS.
Plasmids and siRNA. FLAG-LMP1 and FLAG-LMP1 dCTAR3 have
been described previously (11, 59). Green fluorescent protein (GFP)-
tagged KAP1 (GFP-KAP1) and hemagglutinin (HA)-tagged Ubc9 C93S
(HA-Ubc9 C93S) were purchased from Addgene. Small interfering
(siRNA) targeting Ubc9 or a scrambled sequence was purchased from
Santa Cruz. The BZLF1-expressing plasmid was a gift from Wolfgang
Hammerschmidt (58).
Immunoprecipitation. 293 cells were grown in 100-mm dishes and
transfected with 8 g of DNA using polyethyleneimine. At 48 h posttrans-
fection, cells were lysed in boiling denaturing cell lysis buffer (20 mM Tris,
pH 7.5, 70 mM -mercaptoethanol [-ME], 1 EDTA-free cOmplete
protease inhibitor, 20 M N-ethylmaleimide [NEM]). The lysates were
boiled for 10 min, and 4 volumes of cell lysis buffer (20 mM Tris, pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 EDTA-
free cOmplete protease inhibitor, 20 M NEM) were added to the tubes.
The lysates were centrifuged at 4,000 rpm for 5 min, and the supernatants
were collected and incubated with 1 g of antibody for 1 h at 4°C. Mag-
netic protein G beads (Life Technologies) were added to the samples,
which were then incubated overnight at 4°C. The beads were washed four
times with cell lysis buffer and resuspended in 4 sodium dodecyl sulfate
(SDS; Sigma) loading buffer.
Western blot analysis. Samples were denatured in 4 SDS loading
buffer and boiled for 10 min. The samples were separated by SDS-poly-
acrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene
fluoride (PVDF) membranes (GE). The membranes were blocked with
5% milk in Tris-buffered saline–Tween 20 (TBST) and incubated over-
night at 4°C with primary antibodies. The membranes were washed and
incubated with appropriate horseradish peroxidase-conjugated second-
ary antibodies for 1 h at room temperature. The membranes were washed
again, and bands were visualized with enhanced chemiluminescence re-
agent from GE.
Viral induction by ZTA. EBV WT- and EBV dCTAR3-expressing 293
cells were grown and transfected with ZTA expression plasmids. Cells and
supernatants were collected at 48 h after transfection. Total DNA was
isolated from the cells and 100 l supernatants with a Qiagen DNeasy
blood and tissue kit. The remaining supernatants were added to Raji cells.
Forty-eight hours later the percentages of GFP-positive Raji cells were
determined by flow cytometry (60).
Viral induction by gamma irradiation. EBV WT- and EBV dCTAR3-
expressing 293 cells and paired EBV WT- and EBV dCTAR3-transformed
LCLs were exposed to various doses of irradiation (0 to 10 Gy) (61, 62).
Cells and supernatants were collected at 24 h after transfection. Total
DNA was isolated from the cells and 100 l supernatants with a Qiagen
DNeasy blood and tissue kit. The remaining fluids were added to infect
Raji cells. Forty-eight hours later the percentages of GFP-positive Raji cells
were determined (60).
Real-time PCR. Total RNA was harvested with the use of a Qiagen
RNeasy Plus kit and reverse transcribed with an ABI Prism reverse tran-
scription kit. DNA was harvested using a Qiagen DNeasy blood and tissue
kit. DNA and cDNA were analyzed by real-time PCR with an ABI 7900HT
real-time PCR system. The primers (sequences) used were EBV W-1
(5=-GCAGCCGCCCAGTCTCT-3=), EBV W-2 (5=-ACAGACAGTGC
ACAGGAGCCT-3=), GAPDH-1 (5=-TCATCAGCAATGCCTCCT-3=),
GAPDH-2 (5=-AGGGGCCATCCACAGTCTTC-3=), OriLyt (flank left)-F
(5=-GCGCAACAGTGCCACCAACC-3=), OriLyt (flank left)-R (5=-CAG
GACCTGGCGGTAGTGCAG-3=), pBRLF1-F (5=-GGCTGACATGGAT
TACTGGTC-3=), pBRLF1-R (5=-TGATGCAGAGTCGCCTAATG-3=),
pBZLF1-F (5=-GAGCCACAGGCATTGCTAA-3=), pBZLF1-R (5=-ACCA
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Qp-R (5=-GAACACTCCCTCAGTGGTCA-3=), EFCAB7-F (5=-GCACCT
CTTTCCTGCTGGTG-3=), EFCAB7-R (5=-AGAGCCCTTCTCCAAACG
AT-3=), GABPB2-F (5=-GTGACGCACTTTTCCACCTC-3=), GABPB2-R
(5=-GATTTCTGGCGGAGGAATCT-3=), ZNF-F (5=-GGCGAACTACA
GTCGTGACA-3=), and ZNF-R (5=-CGCTATGCTGTTCACCTTCA-3=)
(63–65). Bio-Rad Universal SYBR green Supermix (Bio-Rad) was used.
Samples and experiments were run in triplicate.
Collecting chromatin fractions. LCLs were grown and treated, and
whole-cell lysates (WCLs) and chromatin fractions were collected. As de-
scribed previously (66), cells were washed and resuspended in 200 l of
CSK buffer {10 mM PIPES [piperazine-N,N=-bis(2-ethanesulfonic acid)],
100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM
dithiothreitol, 0.1 mM ATP, 0.1% Triton X-100, cOmplete protease in-
hibitor}, and pellets were collected following centrifugation at 4,000 rpm
for 5 min. The pellets were washed twice with 1 ml CSK buffer, and
insoluble pellets were resuspended in 50 l of 4 SDS sample buffer and
boiled for 10 min. Western blot and slot blot assays were performed to
examine total KAP1 expression in WCLs and chromatin fractions.
ChIP. Chromatin immunoprecipitation (ChIP) assays were per-
formed with an Active Motif ChIP-IT enzymatic kit (Active Motif) per the
manufacturer’s instruction and as previously described (67). LCLs were
fixed with 37% formaldehyde (final concentration. 1%) for 10 min at
37°C; the reaction was stopped with cold 0.125 M glycine solution for 5
min at room temperature. The cells were then washed twice with phos-
phate-buffered saline and collected in 0.5 ml digestion buffer with 1
protease inhibitors. Chromatin was enzymatically sheared for 10 min at
37°C to obtain fragments with an average size of 200 to 1,000 bp. Sheared
chromatin was incubated overnight at 4°C with protein G magnetic beads
and KAP1 (Abcam) or control (Santa Cruz) antibodies. Immunoprecipi-
tations were performed per the manufacturer’s instructions; cross-linking
was reversed by incubating immunoprecipitated complexes with 5 M
NaCl and RNase A (final concentration, 25 g/ml) for 2 h at 65°C, fol-
lowed by proteinase K (final concentration, 50 mg/ml) treatment for 1 h at
37°C. Real-time PCR was performed to investigate KAP1 binding to lytic
promoters.
Ganciclovir treatment. EBV WT- and EBV dCTAR3-expressing 293
cells and paired EBV WT- and EBV dCTAR3-transformed LCLs were
treated as indicated above, induced (5 Gy irradiation), and treated with
ganciclovir (40 M) (68). At 1 week after treatment, trypan blue exclusion
assays were performed (69), and the fold change in cell death was deter-
mined.
Antibodies. Anti-FLAG (M2) and antiactin (AG-15) antibodies were
purchased from Sigma. Anti-SUMO-1 (clone D-11), anti-HA (clone F-7),
anti-myc (clone 9E10), anti-histone H1 (clone AE-4), anti-EBV EA-R p85
(clone 6G7), and anti-GAPDH (anti-glyceraldehyde-3-phosphate dehy-
drogenase; clone FL-335) antibodies were purchased from Santa Cruz.
Anti-LMP1 antibodies (CS 1 to CS 4) were from Dako, and anti-KAP1
antibodies (clones ab22553 and ab10484) were from Abcam.
RESULTS
LMP1 CTAR3 is not essential for viral replication. We have doc-
umented that LMP1 induces the sumoylation of cellular proteins
by interacting with Ubc9 via CTAR3 (14), which led us to inves-
tigate possible functions of sumoylation during EBV latency. To
investigate whether LMP1-induced sumoylation affects lytic EBV
replication, 293 cells stably expressing WT EBV or EBV dCTAR3
(from Wolfgang Hammerschmidt) were transfected with EBV
ZTA-expressing plasmids. The amounts of viral DNA (relative to
genomic gapdh levels) were determined at 48 h posttransfection,
and the fold changes in the amounts of viral DNA (relative to
those in untreated EBV WT- and EBV dCTAR3-expressing 293
cells) were quantified (Fig. 1A). Supernatants were used to assay
virus infectivity (Fig. 1B) (60). No differences in the production or
release of infectious virus from either cell line were detected,
which confirmed that LMP1 CTAR3 is not required for viral rep-
lication (13, 58). However, noninduced EBV dCTAR3-expressing
293 cells consistently contained significantly (P  0.001) in-
creased levels of viral DNA compared with untreated EBV WT-
expressing 293 cells (Fig. 1C), which correlated with the increased
release of new infectious virus (Fig. 1D). These data suggest that
while LMP1 CTAR3 is not required for efficient viral replication, it
may affect the LMP1-induced maintenance of latency.
LMP1 CTAR3 contributes to the maintenance of EBV la-
tency. To investigate the role of CTAR3 in the maintenance of
latency, we changed the method of induction so that lower levels
of viral reactivation would occur to better mimic endogenous viral
reactivation. The induction of double-stranded DNA damage by
gamma irradiation can promote EBV lytic reactivation (70–73)
and is a common side effect of therapies for EBV-positive lym-
phomas. Exposure of WT EBV- and EBV dCTAR3-expressing 293
cells to graduated doses of gamma irradiation significantly (P 
0.001) increased the release of infectious virus in cells expressing
LMP1 dCTAR3 compared with the amount released in WT EBV-
expressing 293 cells (Fig. 2A). Quantitation of the relative levels of
genomic viral DNA in induced EBV WT- and EBV dCTAR3-ex-
pressing 293 cells revealed that significantly (P  0.001) more viral
DNA was produced in cells containing the virus with the CTAR3
deletion (Fig. 2B). These results were confirmed in similar exper-
iments performed in multiple paired lymphoblastoid cell lines
established by immortalization of B cells with EBV WT or EBV
dCTAR3 (Fig. 2C). Together, these data suggest that LMP1
dCTAR3 helps maintain the virus in its latent state.
LMP1-induced sumoylation helps maintain viral latency.
Because we previously identified a function for LMP1 CTAR3 in
the induction of the sumoylation of cellular proteins (14), we ex-
amined whether protein sumoylation was a specific effector for
regulating viral reactivation in our system. Recently, anacardic
acid and ginkgolic acid were identified to block the formation of
the SUMO-1/SUMO-activating enzyme E1 intermediate, which
resulted in the decreased sumoylation of cellular proteins (74).
Ubc9, the SUMO-conjugating enzyme, is another target for inhib-
iting sumoylation processes, and two mechanisms by which Ubc9
can be targeted is the exogenous expression of Ubc9 C93S, which
renders Ubc9 enzymatically inactive and suppresses the function
of endogenous Ubc9 (28, 75, 76), and the use of siRNA to inhibit
Ubc9 expression (77–79). The effects of anacardic acid, ginkgolic
acid, Ubc9 C93S, and Ubc9-specific siRNA (Ubc9 siRNA) on viral
reactivation were tested.
The SUMO inhibitors, overexpression of Ubc9 C93S, and
knockdown of Ubc9 (with Ubc9 siRNA) all blocked endogenous
protein sumoylation in EBV-expressing 293 cells (Fig. 3A). Treat-
ment of EBV WT-expressing 293 cells and EBV WT-transformed
LCLs with SUMO inhibitors (ginkgolic acid and anacardic acid)
revealed a significant (P  0.001) increase in viral DNA levels
when cells were treated with the SUMO inhibitor compared with
those seen in control cells, which were treated with the vehicle
control (water) and transfected with scrambled siRNA and an
empty expression vector (Fig. 3B and C). No differences were
observed when ginkgolic acid treatment was compared to anac-
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ardic acid treatment (data not shown), suggesting that these drugs
have similar effects on viral reactivation. Transfection of cells with
Ubc9 C93S and knockdown of Ubc9 with siRNA yielded results
similar to those obtained by deletion of LMP1 CTAR3 and drug
treatment (Fig. 3B), further supporting the hypothesis that LMP1-
induced sumoylation contributes to the maintenance of EBV la-
tency. Furthermore, noninduced cells that were treated with the
SUMO inhibitors, transfected with Ubc9 C93S, and transfected
with Ubc9 siRNA exhibited increased viral reactivation compared
to mock-treated, noninduced cells (Fig. 3D). Together, these find-
FIG 1 Deletion of CTAR3 did not affect viral replication but increased background levels of lytic replication. EBV WT- and EBV dCTAR3-expressing 293 cells
were induced by transfection with ZTA expression plasmids or noninduced by transfection with the vector control, and cells and supernatants were collected at
48 h posttransfection. (A) Virus was harvested, and relative viral loads were quantitated by real-time PCR. The fold change in the amount of viral DNA (relative
to that for noninduced EBV WT- and EBV dCTAR3-expressing 293 cells) was determined. (B) Raji cells were exposed to the remaining supernatants. The
percentages of GFP-positive cells were determined by flow cytometry after 48 h. (C) For noninduced cells, the fold change in the amount of viral DNA (relative
to that for noninduced EBV WT-expressing 293 cells) was determined. (D) Raji cells were exposed to the remaining supernatants. The percentages of GFP-
positive cells were determined as described above. Results are shown as means  standard deviations from experiments performed in triplicate.
FIG 2 Deletion of CTAR3 increases cell susceptibility to viral reactivation by irradiation. (A) EBV WT- and EBV dCTAR3-expressing 293 cells were grown and
exposed to various doses of irradiation, and supernatants were collected at 24 h postirradiation. The supernatants were added to Raji cells, and the percentage of
GFP-positive cells was determined after 48 h. (B and C) EBV WT- and EBV dCTAR3-expressing 293 cells (293 EBV cells) (B) and paired EBV WT- and EBV
dCTAR3-transformed LCLs (C) were exposed to 5 Gy of irradiation, and the fold changes in viral loads (relative to the viral load for noninduced cells) were
determined. All results are shown as means  standard deviations from experiments performed in triplicate.
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ings suggest that inhibiting protein sumoylation results in the im-
paired ability of the virus to be maintained in a latent state and that
EBV-expressing cells are more susceptible to reactivation of lytic
replication.
Inhibition of LMP1-induced sumoylation makes cells more
susceptible to antiviral treatment. One proposed method for
treating EBV-associated malignancies is the induction of EBV lytic
reactivation in latently infected tumor cells (80–84), which would
result in cell susceptibility to cytotoxic antiviral drugs (85). To
investigate whether inhibition of LMP1-induced sumoylation re-
sults in increased cellular death in response to antiviral therapy,
irradiated and mock-irradiated EBV WT-transformed LCLs, EBV
dCTAR3-transformed LCLs, and EBV WT-transformed LCLs
treated with SUMO inhibitors were treated with ganciclovir
(GCV) or a vehicle control (water), and cell death was assayed by
trypan blue exclusion (Fig. 4A). The results showed that GCV-
induced LCL death was significantly (P  0.001) increased in in-
duced cells compared with noninduced cells, confirming that
irradiation can induce viral reactivation. GCV-treated EBV
dCTAR3-transformed LCLs and EBV WT-transformed, SUMO
inhibitor-treated LCLs exhibited increased cell death compared
with GCV-treated EBV WT LCLs, suggesting that viral reactiva-
tion increased in the absence of CTAR3 and inhibition of sumoy-
lation processes. Furthermore, the death of LCLs transformed
with EBV dCTAR3 or treated with a SUMO inhibitor was signif-
icantly (P  0.001) greater than that of LCLs transformed with the
EBV WT after mock irradiation, which verified that deletion of
CTAR3 and inhibition of sumoylation processes result in a leakier
hold on latency.
To confirm the role of sumoylation processes in increased sus-
ceptibility to GCV treatment, similar experiments were per-
formed in EBV WT-expressing 293 cells, EBV dCTAR3-express-
FIG 3 Inhibition of LMP1-induced sumoylation increases lytic viral replication following irradiation. (A) EBV-expressing 293 cells were transfected with Ubc9
C93S, Ubc9 s9RNA, or control expression vectors. At 24 h posttransfection, cells were treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic
acid). Whole-cell lysates were collected at 48 h posttransfection. Western blot analyses were performed for SUMO-1, Ubc9, and GAPDH (loading control). (B)
EBV WT-expressing 293 cells were treated with a vehicle control and transfected with scrambled siRNA and an empty expression vector, treated with SUMO
inhibitors (25 M anacardic acid and 25 M ginkgolic acid), transfected with Ubc9 C93S, or transfected with Ubc9 siRNA. (C and D) EBV WT-transformed
LCLs were treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic acid) or the vehicle control and induced (C) or noninduced (D). Fold
changes in viral loads were determined 24 h after irradiation. All results are shown as means  standard deviations from experiments performed in triplicate.
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ing 293 cells, EBV WT-expressing 293 cells treated with a SUMO
inhibitor, EBV WT-expressing 293 cells with exogenous expres-
sion of Ubc9 C93S, and EBV WT-expressing 293 cells transfected
with Ubc9 siRNA (Fig. 4B). As a control, EBV WT-expressing 293
cells were treated with water and transfected with scrambled
siRNA and an empty expression vector. Inhibition of sumoylation
processes by deletion of CTAR3, treatment with ginkgolic acid
and anacardic acid, overexpression of Ubc9 C93S, and knock-
down of Ubc9 resulted in significantly (P  0.001) increased sus-
ceptibility to GCV treatment. Together, these data imply that
inhibition of LMP1 CTAR3-mediated protein sumoylation in-
creases viral reactivation, which in turn results in increased sus-
ceptibility to antiviral drugs.
KAP1 is a target of LMP1 CTAR3-induced sumoylation. To
identify a cellular target of LMP1-induced sumoylation that might
be implicated in the progression of lytic replication, we first fo-
cused on a members of the tripartite motif family (KAP1). KAP1
can function as a transcriptional repressor (50, 86), and the mod-
ification of KAP1 by SUMO at lysine 554, 575, 676, 750, 779,
and/or 804 aids its repressive functions (54, 87–92). Sumoylated
KAP1 has been reported to bind to and repress Kaposi’s sarcoma-
associated herpesvirus (KSHV) lytic promoters (93); however, its
function during the EBV life cycle remains unexamined. These
findings led us to propose that LMP1-mediated sumoylation of
KAP1 helps in the maintenance of EBV latency by inhibiting lytic
replication.
The endogenous sumoylation of KAP1 during latent EBV in-
fection was examined using the paired BL41 cell lines that were
either EBV negative, latently infected with EBV WT, or latently
infected with the EBV P3HR1 mutant (Fig. 5A) (39, 56, 57). The
results showed that increased levels of sumoylated KAP1 were
detected in EBV WT-expressing BL41 cells compared with EBV-
negative BL41 cells, which suggested that the sumoylation of
KAP1 is increased during EBV latency. In addition, cells latently
infected with the P3HR1 mutant, which lacks EBNA2, resulting in
undetectable levels of LMP1 expression (39, 56, 57), showed lower
levels of sumoylated KAP1 than EBV WT-expressing BL41 cells.
Densitometric analysis of repeat experiments confirmed these
findings (Fig. 5B), which led us to propose that the LMP1-medi-
ated regulation of sumoylation processes significantly contributes
to the sumoylation of KAP1 during EBV latency.
We previously documented a function for LMP1 CTAR3 in the
induction of the sumoylation of cellular proteins (14), and results
from paired EBV WT- and EBV dCTAR3-transformed LCLs
showed that LMP1 CTAR3 is required for the sumoylation of
KAP1 during viral latency (Fig. 5C). Sumoylated KAP1 was de-
tected in all LCLs (Fig. 5A); however, the levels of sumoylated
KAP1 were significantly (P  0.001) increased in all EBV WT-
expressing cells compared with those in EBV dCTAR3-expressing
cells (Fig. 5D), which suggests that the sumoylation of KAP1 oc-
curred in a CTAR3-dependent manner.
The importance of LMP1 and LMP1 CTAR3 in the observed
increased sumoylation of KAP1 was confirmed by overexpression
experiments in 293 cells (Fig. 5E). Taken together, these findings
document that KAP1 is sumoylated during latent EBV infection
and EBV-induced sumoylation of KAP1 is highly dependent on
LMP1, specifically, CTAR3. Because we proposed that the LMP1
CTAR3-mediated sumoylation of KAP1 contributes to the main-
tenance of EBV latency, next we investigated the role of LMP1
CTAR3-induced sumoylation on a known function of KAP1.
The association of KAP1 with chromatin increases with
LMP1-induced sumoylation. While KAP1 lacks a DNA-binding
domain, it associates with KRAB-containing zinc finger proteins
(KRAB-ZFPs), which in turn bind gene promoter regions (53, 86,
87). The sumoylation of KAP1 is required for its repressive func-
tion at these promoter regions (87, 90–92), so the effect of LMP1-
induced sumoylation on the ability of KAP1 to associate with
cellular chromatin was examined. The results showed that LMP1-
expressing cells contained increased detectable levels of sumoy-
lated KAP1 (Fig. 6A, WCL), which confirms that sumoylation of
KAP1 increases in the presence of LMP1. Following separation of
the chromatin and supernatant fractions, sumoylated KAP1 was
detected only in the chromatin fractions of LMP1-expressing cells
(Fig. 6A, chrom), while control-expressing cells contained almost
undetectable KAP1 levels. In EBV WT- and EBV dCTAR3-trans-
formed LCLs and SUMO inhibitor-treated EBV WT-transformed
FIG 4 Inhibition of sumoylation increases cell susceptibility to cytotoxic antiviral drugs following irradiation. (A) EBV WT-transformed LCLs, EBV dCTAR3-
transformed LCLs, and SUMO inhibitor (25 M anacardic acid and 25 M ginkgolic acid)-treated EBV WT-transformed LCLs were irradiated (5 Gy; induced)
or noninduced. (B) EBV WT-expressing 293 cells, EBV dCTAR3-expressing 293 cells, and EBV WT-expressing 293 cells treated with water and transfected with
scrambled siRNA and an empty expression vector, treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic acid), transfected with a Ubc9 C93S
expression plasmid, or transfected with Ubc9 siRNA were induced or noninduced. At 24 h postirradiation, cells were treated with ganciclovir (10 mg/ml) or
vehicle control (water). After 1 week, trypan blue exclusion assays were performed and fold changes in cell death were calculated. Results are shown as means 
standard deviations from experiments performed in triplicate.
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LCLs (Fig. 6B), densitometric analysis of repeat experiments
showed a significant (P  0.001) 40 to 60% decrease in the
amount of chromatin-associated KAP1 in cells expressing LMP1
dCTAR3 compared with that in cells expressing the LMP1 WT.
Similar results were observed when EBV WT-transformed LCLs
were treated with a SUMO inhibitor for 24 h before harvesting.
Furthermore, similar experiments were performed in 293 cells
where LMP1-mediated dysregulation of sumoylation processes
was targeted by deletion of CTAR3, treatment with SUMO inhib-
itors, overexpression of Ubc9 C93S, and knockdown of Ubc9 (Fig.
6C). These findings suggest that LMP1 induced the sumoylation
of KAP1, which increased the association of KAP1 with cellular
chromatin.
ChIP analyses were performed to confirm that KAP1 was asso-
ciating with known cellular promoters, specifically, zinc finger
(ZNF) genes, GABPB2, and EFCAB7 (65). Input controls were
positive for these three promoters, and the fold change in DNA
binding (relative to that for the input controls) was determined. In
both EBV-transformed LCLs and EBV-expressing 293 cells, inhi-
bition of LMP1 CTAR3-induced protein sumoylation signifi-
cantly (P  0.001) inhibited the association of KAP1 with the
GABPB2 and EFCAB7 promoters (Fig. 6D and E). While KAP1
binding to the ZNF genes was not detected in the LCLs, KAP1 did
associate with ZNF genes in a CTAR3-dependent manner in EBV-
expressing 293 cells (Fig. 6E). Inhibition of cellular sumoylation
processes abrogated this interaction.
Together, these results confirm that LMP1 expression signifi-
cantly (P  0.001) increases the association of KAP1 with cellular
chromatin and select cellular promoters. Inhibition of LMP1-in-
duced sumoylation processes abrogated this increase. These find-
ings demonstrate that LMP1-mediated sumoylation increases the
association of KAP1 with chromatin, which leads us to propose
that LMP1 may inhibit lytic gene expression through the associa-
tion of sumoylated KAP1 with viral chromatin.
KAP1 binds to EBV OriLyt and the immediate early promot-
ers. Interestingly, sumoylation of KAP1 is reported to help main-
tain KSHV latency by repressing KSHV lytic promoters (93).
When KAP1 is desumoylated, it no longer associates with viral
FIG 5 LMP1 expression correlates with endogenous KAP1 sumoylation in a CTAR3-dependent manner. (A) Denaturing immunoprecipitations (IP) were
performed on BL41 EBV-negative, BL41 EBV-positive, and BL41 P3HR1 mutant-infected cells with SUMO-1-specific antibodies or IgG control antibodies.
Western blot (WB) analyses were used to detect KAP1 covalently modified by SUMO-1. (B) Densitometric analysis of repeat experiments was performed. Results
are shown as means  standard deviations from experiments performed in triplicate. pos, positive; neg, negative. (C) Western blot analyses were used to detect
KAP1 covalently modified by SUMO-1 in paired EBV WT- and EBV dCTAR3-transformed LCLs with SUMO-1-specific antibodies or IgG control antibodies.
(D) Densitometric analysis of repeat experiments was performed. Results are shown as means  standard deviations from experiments performed in triplicate.
(E) 293 cells were transfected with GFP-KAP1 and either FLAG-LMP1, FLAG-LMP1 dCTAR3, or vector control expression constructs. At 48 h posttransfection,
whole-cell lysates were collected and immunoblotting assays were performed to detect LMP1 (FLAG) and KAP1 (GFP) levels. GAPDH was used as a loading
control.
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promoters and lytic viral replication is initiated (93). To examine
whether LMP1-induced sumoylation of KAP1 serves a similar re-
pressive function on EBV lytic promoters, ChIP analyses were
performed to determine the association of KAP1 with OriLyt, Qp,
and the ZTA, RTA, BALF5, BNRF1, and BCRF1 promoters. Input
controls were positive for all promoters examined, and the fold
change in DNA binding (relative to that for the input controls)
was determined. The results showed that KAP1 associated with
OriLyt as well as the ZTA and RTA promoters in EBV WT-trans-
formed LCLs (Fig. 7A) from our sets of paired LCLs. However,
significantly (P  0.001) less KAP1 associated with these promot-
ers in paired LCLs when sumoylation processes were inhibited (in
EBV dCTAR3-transformed LCLs and EBV WT-transformed
LCLs treated with a SUMO inhibitor). Similar results were ob-
served in EBV-expressing 293 cells where LMP1-induced sumoy-
lation was inhibited by deletion of CTAR3, treatment with the
SUMO inhibitor, and transfection of Ubc9 C93S or Ubc9 siRNA
(Fig. 7B). In addition, the data revealed that neither KAP1 nor the
IgG control interacted with anything bound to select early gene
promoters (BALF5), late gene promoters (BNRF1), or latency-
FIG 6 LMP1 CTAR3-induced sumoylation regulates KAP1 function. (A) Whole-cell lysates, chromatin-enriched extracts (chrom), and the corresponding
supernatants (sup) collected from 293 cells transfected with LMP1 expression constructs or control expression constructs; (B) paired EBV WT- and EBV
dCTAR3-transformed LCLs and EBV WT-transformed LCLs treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic acid); (C) 293 cells
transfected with a vector control expression construct and scrambled siRNA, LMP1 dCTAR3 expression constructs, LMP1 expression constructs, LMP1
expression constructs treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic acid), LMP1 and Ubc9 C93S expression constructs, and LMP1
expression constructs treated with Ubc9 siRNA. (A) Western blot analyses were performed, and KAP1 and GAPDH levels were detected. (B and C) Densitometric
analysis of repeat immunoblots and slot blot analyses were performed, and the KAP1 levels in chromatin fractions relative to the levels in whole-cell lysates were
determined. Fold changes in KAP1 chromatin association were determined. (D and E) Paired EBV WT- and EBV dCTAR3-transformed LCLs and EBV
WT-transformed LCLs treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic acid) (D) and EBV WT-expressing 293 cells, EBV dCTAR3-
expressing 293 cells, and EBV WT-expressing 293 cells treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic acid), transfected with Ubc9
C93S-expression constructs, or transfected with Ubc9 siRNA (E) were grown, and chromatin immunoprecipitations were performed with KAP1-specific
antibodies or control IgG antibodies. Real-time PCR analyses were performed to examine the KAP1 association with the GABPB2, EFCAB7, and ZNF gene
promoters. The fold change in DNA binding (relative to that for the input controls) was determined. Results are shown as means  standard deviations from
experiments performed in triplicate.
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associated promoters (Qp) (Fig. 7A and B). No significant differ-
ences between KAP1 and IgG control antibody binding to the
BCRF1 promoter were observed, which suggests that KAP1 does
not bind to the BCRF1 promoter. These results demonstrate that
LMP1 CTAR3 promotes the binding of KAP1 to EBV OriLyt and
the immediate early promoters and inhibition of cellular sumoy-
lation processes abrogates this response. We propose that the
binding of KAP1 at these sites promotes the transcriptional re-
pression that contributes to the maintenance of viral latency.
Together, these findings provide additional evidence that
CTAR3 is a distinct regulatory region of LMP1 and identify a
function and mechanism of action for LMP1-induced sumoyla-
tion, acting through CTAR3, in the maintenance of EBV latency.
DISCUSSION
Earlier, we identified a novel function for LMP1 CTAR3 in the
regulation of cellular sumoylation processes during EBV latency
(14). Our new findings now point to a role for CTAR3 and the
induction of sumoylation by LMP1 in the maintenance of EBV
latency. Additionally, we found that KAP1 is a cellular target of
LMP1 CTAR3-induced sumoylation that can contribute to LMP1
CTAR3-mediated maintenance of EBV latency. These data are the
first to identify a role for KAP1 in the maintenance of EBV latency.
Together, these findings provide further support for the functions
of LMP1 CTAR3, specifically, in the dysregulation of cellular
sumoylation processes. They also highlight the importance of
LMP1-induced sumoylation in the EBV life cycle.
The finding that noninduced cells expressing LMP1 lacking
CTAR3 exhibited increased levels of viral DNA led us to study the
role of CTAR3 in the maintenance of EBV latency. However, while
transfection of BZLF1 expression plasmids is an efficient inducer
of lytic reactivation in EBV-expressing 293 cells, we found that it
was not ideal for these studies due to high transfection efficiencies
and high levels of viral reactivation. Instead, we used induction of
double-stranded DNA damage by irradiation (61, 62, 71–73),
which proved to induce lower levels of viral reactivation and facil-
itated examination of the endogenous reactivation of EBV in
LCLs. The finding that LCLs became susceptible to GCV treat-
ment when LMP1-induced sumoylation was inhibited and cells
were irradiated demonstrates that viral reactivation occurred and
progressed to lytic replication. Furthermore, the finding that non-
FIG 7 KAP1 binds to the EBV OriLyt and the immediate early promoters. Paired EBV WT-transformed LCLs, EBV dCTAR3-transformed LCLs, and EBV
WT-transformed LCLs treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic acid) (A) and EBV WT-expressing 293 cells, EBV dCTAR3-
expressing 293 cells, and EBV WT-expressing 293 cells treated with the vehicle control (water) and transfected with scrambled siRNA and an empty expression
vector and treated with SUMO inhibitors (25 M anacardic acid and 25 M ginkgolic acid), transfected with Ubc9 C93S expression constructs, or transfected
with Ubc9 siRNA (B) were grown, and chromatin immunoprecipitations were performed with KAP1-specific antibodies or control IgG antibodies. Real-time
PCR analyses were done for OriLyt, the ZTA promoter, the RTA promoter, the BALF5 promoter, the BNRF1 promoter, the BCRF1 promoter, and Qp. The fold
change in DNA binding (relative to input controls) was determined. Results are shown as means  standard deviations from experiments performed in triplicate.
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irradiated EBV dCTAR3-transformed LCLs were susceptible to
GCV treatment provides additional support to our claim that
these cells are leakier than their EBV WT-transformed LCL coun-
terparts.
In the course of these and our previous studies (14), we used
four different methods to inhibit LMP1-induced sumoylation: (i)
deletion of CTAR3, (ii) overexpression of enzymatically inactive
Ubc9, (iii) treatment of cells with a combination of anacardic acid
and ginkgolic acid, and (iv) siRNA-mediated knockdown of Ubc9.
Due to the increased sumoylation observed in multiple malignan-
cies, cellular sumoylation processes are proposed targets for anti-
cancer therapies (26, 28). Ubc9 can specifically be targeted with
siRNA (77–79), and Ubc9 function can be suppressed by expres-
sion of a dominant negative Ubc9 mutant (Ubc9 C93S) (75, 76).
Inhibition of LMP1-induced protein sumoylation by any of the
four tested methods partially abolished the inhibition of lytic rep-
lication in EBV-positive cells, which resulted in increased levels of
viral DNA in noninduced and induced cells. In all experiments,
inhibition of cellular sumoylation processes produced results sim-
ilar to those observed with deletion of CTAR3, which suggests that
any of the other tested methods of inhibiting sumoylation would
be potential mechanisms by which LMP1-induced sumoylation
could be inhibited in vivo during EBV latency. Two novel sumoy-
lation inhibitors, spectomycin B1 and davidiin, have recently been
identified (94, 95). Davidiin, an ellagitannin, functions in a similar
manner as ginkgolic acid and anacardic acid and inhibits the for-
mation of the SUMO-activating enzyme–SUMO-1 intermediate
(95). Spectomycin B1 binds to Ubc9 and inhibits the SUMO-Ubc9
intermediate (94). Because our studies targeted the same steps of
the sumoylation process, we propose that treatment of EBV-pos-
itive cells with either davidiin or spectomycin B1 would abrogate
the LMP1 sumoylation-dependent maintenance of EBV latency,
promoting viral reactivation.
We now document that KAP1 sumoylation, a well-studied
process (54, 88–92), occurs in an LMP1 CTAR3-dependent man-
ner. While KAP1 sumoylation has been documented during latent
KSHV infection (93), this is the first report to show endogenous
sumoylation of KAP1 during latent EBV infection. The mecha-
nism by which KAP1 is sumoylated during EBV latency remains
unknown, but there are multiple possible manners by which the
sumoylation of KAP1 may occur. KAP1 undergoes autosumoyla-
tion following its binding to Ubc9 (90). We documented that
LMP1 CTAR3 interacts with Ubc9 (14), so following the interac-
tion of LMP1 with Ubc9, Ubc9 may bind KAP1, which results in
the direct SUMO conjugation of KAP1 (90). Supporting this idea
is the finding that KAP1 serves as a SUMO E3 ligase for interferon
regulatory factor 7 (IRF7) (96), which was the first identified tar-
get of LMP1 CTAR3-induced sumoylation (46). We previously
showed that the LMP1-induced sumoylation of IRF7 is dependent
on cooperation between LMP1 CTAR2 and LMP1 CTAR3 (46).
We proposed that sumoylation of IRF7 was due to LMP1 bringing
together IRF7, which indirectly interacts with CTAR2 (38, 42),
and Ubc9, which interacts with CTAR3 (14). Therefore, the pos-
sibility exists that KAP1 is also associated with the LMP1/Ubc9/
IRF7 complex, resulting in KAP1 sumoylation as well as the action
of KAP1 as a SUMO ligase for IRF7. Finally, it is possible that the
sumoylation of KAP1 is a result of its interactions with down-
stream targets of LMP1. For instance, KAP1 also interacts with
NF-B and STAT3 (97), which are known targets of SUMO-1
(98–101) and downstream targets of LMP1-induced signaling (8,
38, 102, 103), and the ability of KAP1 to interact with known
sumoylated proteins may promote the sumoylation of KAP1 itself.
Deciphering the mechanism by which LMP1 mediates the sumoy-
lation of KAP1 will be part of our future studies into the function
of LMP1 CTAR3 and LMP1-induced protein sumoylation.
KAP1 is a well-characterized transcriptional corepressor (86)
that binds to thousands of sites in the human genome via KRAB-
ZFPs (53, 86, 87) when it is sumoylated (53). Here we show KAP1
associates with cellular chromatin and select cellular promoters
(65) in an LMP1 CTAR3-induced sumoylation-dependent man-
ner. These findings suggest that one mechanism by which LMP1
can inhibit gene expression is via the sumoylation of KAP1, which
promotes KAP1 chromatin association and transcriptional re-
pression.
In addition to associating with cellular chromatin, we now
document that KAP1 also associates with viral DNA. KAP1 binds
to EBV OriLyt and the immediate early promoters ZTA and RTA
but not select early, late, and latency-associated promoters. The
binding of KAP1 to these promoters occurs in a sumoylation-
dependent manner in both LCLs and EBV-expressing 293 cells.
Due to the documented abundance of repressive histone methyl-
ation (63), the specific piece of OriLyt that was analyzed in these
studies was OriLyt Flank (63), which comprises auxiliary compo-
nents of OriLyt that contribute to and enhance the activity of
OriLyt (104). The ability of KAP1 to bind to the core components
of OriLyt remains to be examined; however, we propose that mul-
tiple KAP1-binding sites which contribute to SUMO-dependent
repression of lytic reactivation are present. In addition, the wide
array of functions attributed to KAP1 (53) suggests that investiga-
tion of the effects of LMP1 CTAR3 in DNA repair responses, as
well as in the maintenance of EBV genomic integrity, may yield
interesting results.
Recently, it was documented that DNA-damaging agents, in-
cluding hydrogen peroxide, induce EBV reactivation (70). Hydro-
gen peroxide and the induction of reactive oxygen species are
known to result in lower levels of overall protein sumoylation due
to their effects on the Ubc9-SUMO interaction (105). Therefore,
both reports add direct support for our hypothesis that LMP1-
induced sumoylation affects the maintenance of EBV latency.
In summary, we propose that during latent EBV infection,
when LMP1 is expressed (type II and type III EBV latency),
sumoylation processes are dysregulated, resulting in increased
protein sumoylation. KAP1 is sumoylated, resulting in transcrip-
tional repression, including the repression of lytic viral promoters.
Inhibition of LMP1-induced sumoylation by deletion of LMP1
CTAR3, treatment with anacardic acid and ginkgolic acid, expres-
sion of enzymatically inactive Ubc9, knockdown of Ubc9, or po-
tentially even treatment with hydrogen peroxide results in the loss
of KAP1 sumoylation and a leakier switch from latent infection to
lytic replication. The result is the increased ability to induce lytic
replication. Thus, because lytic replication is necessary for antivi-
ral drugs to be activated and exert their cytotoxic effects, these
findings identify methods by which latent EBV infections can be
disrupted and made susceptible to such approaches.
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